Substance P Antagonists vs Thymosin Beta-4
NK1 receptor blockers that reduce pain signals and nausea at the source
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Substance P Antagonists
150–150 mg
Thymosin Beta-4
2–5 mg
Frequency
Substance P Antagonists
Once daily
Thymosin Beta-4
Twice weekly
Administration
Substance P Antagonists
Oral capsule
Thymosin Beta-4
Subcutaneous injection
Cycle length
Substance P Antagonists
Ongoing/indefinite
Thymosin Beta-4
8-12 weeks
Onset speed
Substance P Antagonists
Moderate (1-2 weeks)
Thymosin Beta-4
Moderate (1-2 weeks)
Evidence level
Substance P Antagonists
Moderate human trials (Phase 1-2)
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Benefit ratings
Anti-Nausea & Antiemetic
Pain Modulation
Neuroprotection
Wound Healing
Inflammation Reduction
Tissue Regeneration
Compound specifications
Substance P Antagonists
Molecular formula
C23H21F7N4O3
Molecular weight
534.4 g/mol
Half-life
9-13 hours (elimination half-life)
Bioavailability
Approximately 60-65% oral bioavailability; food may increase absorption
CAS number
170729-80-3
Thymosin Beta-4
Molecular formula
C212H350N56O78S
Molecular weight
4963
Half-life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS number
77591-33-4
Dosing compared
Substance P Antagonists
Intravenous
150 mg (fosaprepitant)
Single dose, 30 min before chemotherapy on day 1 · One dose per chemotherapy cycle
FDA-approved single-dose IV prodrug regimen, with a 5-HT3 antagonist and corticosteroid [5].
Oral
125 mg on day 1, then 80 mg on days 2-3 (aprepitant)
Once daily · 3-day course per chemotherapy cycle
FDA-approved oral regimen: 125 mg 1 hour before chemotherapy, then 80 mg each morning on days 2 and 3 [5].
Thymosin Beta-4
Subcutaneous injection
2-5 mg (community injectable practice for 'TB-500')
Once or twice weekly · 4-6 week loading phase, then weekly maintenance
Documented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.
Topical ophthalmic (eye drops)
0.1% (1 mg/mL) RGN-259 solution, 1 drop
Several times daily (e.g. up to 5x/day) · 4 weeks
0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].
Intravenous injection
450-1200 mg
IV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeks
Doses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].
Best suited for
Substance P Antagonists
Managing severe nausea from cancer treatments
Substance P Antagonists is particularly well-suited for individuals focused on managing severe nausea from cancer treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic pain reduction
Substance P Antagonists is particularly well-suited for individuals focused on chronic pain reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving quality of life during intensive medical therapy
Substance P Antagonists is particularly well-suited for individuals focused on improving quality of life during intensive medical therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Side effects
Substance P Antagonists
Common
- Headache
- Fatigue or weakness
- Constipation
Uncommon
- Loss of appetite
- Dizziness
Serious
- Stevens-Johnson Syndrome (SJS)
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Safety & evidence
Substance P Antagonists
Evidence level
Moderate human trials (Phase 1-2)
FDA status
FDA approved for this use
Safety overview
Aprepitant (the primary NK1 antagonist) has been FDA-approved since 2003 with extensive safety data in over 50,000 cancer patients receiving highly emetogenic chemotherapy. Most common adverse events are mild to moderate—headache (15-20%), fatigue, and constipation—which are often difficult to attribute solely to aprepitant versus underlying malignancy or chemotherapy effects. Serious but rare adverse events include Stevens-Johnson syndrome (extremely uncommon) and QT prolongation (in susceptible individuals), requiring baseline ECG evaluation in high-risk patients.
Contraindications
- Severe hypersensitivity to aprepitant or any component
- Concurrent use with certain other medications that affect the liver
- Severe cardiac conditions
Thymosin Beta-4
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- Active systemic infections
- Severe immunosuppression
- Hypersensitivity to thymosin or any component
- Pregnancy (insufficient safety data)
Which is right for you?
Choose Substance P Antagonists if...
- Managing severe nausea from cancer treatments
- Chronic pain reduction
- Improving quality of life during intensive medical therapy
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation